Reunion Neuroscience is a clinical stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.

The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.

Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

MANAGEMENT TEAM

Greg Mayes

Greg Mayes

President & Chief Executive Officer

Edward Smith

Edward Smith

Chief Financial Officer

Nathan Bryson, PhD

Dr. Nathan Bryson

Chief Science Officer

Robert Alexander

Dr. Robert Alexander

Chief Medical Officer

Beatrix

Beatrix Taylor, MSc, RAC

Senior Vice President, Clinical Development & Regulatory Affairs

Mark-Theeuwes

Mark Theeuwes

Chief Operating Officer

ADVISORY BOARD

Anita Clayton

Dr. Anita H. Clayton

Advisor

Dr. Michael Ehlers

Dr. Michael Ehlers

Advisor

Dr. Sidney H. Kennedy

Dr. Sidney H. Kennedy

Advisor

Sheryl Kingsberg

Dr. Sheryl Kingsberg

Advisor